Peptide research literature uses precise language where small distinctions carry real meaning. Words like “efficacy,” “bioavailability,” and “significant” have specific scientific definitions that diverge from everyday usage. Those gaps are where most misinterpretation happens, both in reading studies and in evaluating secondary sources that borrow research language loosely. This guide is a terminology reference organized by concept. Each term is defined concisely with the distinction that matters most in practice. For the broader skill of reading and evaluating studies, see how to read a research study on peptides.
Key Research Facts: Understanding Peptide Research Terminology
- Peptide and protein refer to the same type of molecule, length is the only distinction and the boundary is not rigid
- Purity on a COA is measured by HPLC and reflects the target compound as a percentage of total signal, the remaining percentage is not biologically neutral
- Half-life describes how fast a compound clears a system, not how long its biological effects last
- Half-life describes how fast a compound clears a system, not how long its biological effects last
- Mechanism of action and observed effect are separate things, many compounds produce measurable effects whose mechanism is not yet fully characterized
Compound and Structure Terms
Peptide: a chain of amino acids connected by peptide bonds. The working definition for research purposes is under 50 amino acid residues. Above that threshold the compound is typically called a protein. The boundary is not rigid and the distinction is less important than sequence, the specific order of amino acids, which determines everything about how a compound behaves.
Analogue: a synthetic compound structurally related to a native peptide but modified by design. Modifications typically target stability, receptor affinity, or half-life. An analogue is not an imitation. It is a purpose-built research tool based on naturally occurring biology.
Native peptide: a naturally occurring sequence the body produces. The contrast with an analogue is important when interpreting study results. A native peptide and its analogue may share a receptor target but behave very differently in a research system.
Agonist: a compound that binds a receptor and activates it. Antagonist: a compound that binds the same receptor without activating it, blocking access for agonists. Most well-studied research peptides are agonists.
Receptor binding affinity: how strongly a compound binds its target receptor, usually expressed as a Ki or EC50 value. Lower values mean tighter binding at lower concentrations. This is distinct from efficacy, which describes the maximum effect the compound can produce regardless of concentration. For foundational context on how sequence and structure govern these interactions, see peptides vs proteins: what’s the difference and how peptides are created: natural vs synthetic.
Purity and Quality Terms
Purity: the target compound expressed as a percentage of total sample content, measured by HPLC. A purity of 98% means 2% of the sample is something else. That something else is not inert. Impurities are typically truncated sequences, deletion sequences, oxidized variants, or residual synthesis reagents, none of which are biologically neutral in a research context.
HPLC (high-performance liquid chromatography): the analytical method used to measure purity. It separates sample components and produces a chromatogram, a graph of peaks. The purity percentage is derived from the relative size of the target peak against all peaks combined. The chromatogram image is more informative than the headline percentage alone.
Mass spectrometry: the analytical method used to confirm identity. Where HPLC measures proportion, mass spectrometry measures molecular weight and confirms the compound is actually the intended sequence. Both are required for a complete certificate of analysis.
COA (certificate of analysis): the batch-specific document that records HPLC purity, mass spectrometry confirmation, and the analytical methods used to generate those results. A COA that is not batch-specific has no evidentiary value in a research setting.
Lyophilized: freeze-dried, with water removed under vacuum to extend shelf stability. Reconstitution: the process of dissolving lyophilized powder into solution for laboratory use. For solubility variables and reconstitution strategies, see peptide solubility and reconstitution.
Pharmacokinetic Terms
Pharmacokinetics: the study of what a biological system does to a compound over time. Absorption, distribution, metabolism, and elimination, abbreviated ADME. Not to be confused with pharmacodynamics, which describes what the compound does to the system.
Bioavailability: the proportion of an administered dose that reaches systemic circulation in an active form. Intravenous administration is the reference point at 100%. Subcutaneous and intraperitoneal routes are lower. Oral bioavailability for most peptides is near zero due to enzymatic breakdown in the gut before absorption.
Half-life: the time it takes for the concentration of a compound in a system to fall by half. It describes clearance rate, not duration of biological effect. These are two separate timelines that are frequently conflated. A compound can clear circulation in minutes while its downstream receptor effects run for hours.
Selectivity: a compound’s preference for one receptor subtype over others within the same receptor family. Specificity: whether a compound’s effects are attributable to a single defined mechanism or multiple pathways. Neither term guarantees the absence of unintended effects. Both describe degrees of preference, not absolute exclusivity.
For a compound-level illustration of how pharmacokinetic engineering extends half-life in practice, see semaglutide research overview.
Research Methodology Terms
In vitro: experiments conducted outside a living organism, cells in a dish, isolated tissue, or cell-free systems. Establishes whether a compound interacts with a specific target under controlled conditions. Cannot establish how that interaction behaves in a living system.
In vivo: experiments conducted within a living organism. In peptide research this almost always means a rodent model. Richer than in vitro but not predictive of human outcomes. Rodent physiology differs from human physiology in ways that matter for interpreting results.
Control group: the baseline in any experiment. Receives everything the treatment group receives except the compound being studied. Without an adequate control, a study cannot establish causation, only description.
Blinding: whether researchers measuring outcomes know which subjects received the compound. Double-blinded means neither subjects nor researchers know until after data collection. Reduces measurement bias, the tendency to find what you expect to find.
Dose-response relationship: when increasing the dose produces a proportionally greater effect and decreasing it reduces the effect. One of the more reliable indicators that an observed result is genuinely caused by the compound rather than experimental noise.
Statistical significance and p-value: a p-value below 0.05 means less than a 5% probability the result was due to chance. It does not mean the effect was large or practically meaningful. Effect size, how large the observed change actually was, is the measure that tells you that. For how these terms apply when evaluating combined research protocols, see peptide stacks research overview.
Terms That Get Misused Most Often
Efficacy vs potency: not synonyms. Potency describes how much of a compound is needed to produce a given effect. Efficacy describes the maximum effect a compound can produce regardless of concentration. Calling a compound potent says nothing about how significant its effects actually are.
Significant: in a scientific paper this means statistically significant, a mathematical statement about probability. It does not mean large, important, or clinically meaningful. A very small effect in a large sample can be statistically significant.
Suggests, may indicate, is consistent with: hedge phrases meaning the authors are inferring, not concluding. The data does not definitively establish the claim being made. Treating these phrases as conclusions is where most secondary source distortion originates.
Mechanism of action vs observed effect: mechanism describes how a compound produces its effect at a molecular level. Observed effect is what was measured in the study. Many compounds produce measurable effects whose mechanism is not yet fully characterized. Effect can be observed before mechanism is understood.
RUO, research use only: the regulatory designation meaning a compound is intended exclusively for non-clinical laboratory research and is not approved or validated for diagnostic, therapeutic, or human use. BioStrata Research supplies semaglutide and retatrutide under this framework as research-grade lyophilized compounds with full batch COA documentation.
FAQs, Understanding Peptide Research Terminology
What is the difference between efficacy and potency?
Potency describes how much of a compound is needed to produce a given effect. Efficacy describes the maximum effect a compound can produce regardless of concentration. A compound can be highly potent with a low ceiling, or require high concentrations but produce a large maximum effect. When research calls a compound potent, that says nothing about how significant the effect actually is.
What does mechanism of action mean and why does it matter?
Mechanism of action describes how a compound produces its biological effect at a molecular level: which receptor it binds, which signaling pathway it activates or inhibits, what cellular events follow downstream. This is distinct from observed effect, what was measured in the study. A compound with a well-characterized mechanism is easier to study systematically and to interpret across different models and species.
What is the difference between a peptide analogue and a native peptide?
A native peptide is a naturally occurring sequence the body produces. An analogue is a synthetic version that shares structural similarities but differs by design. Modifications might improve stability, extend half-life, or change receptor binding affinity. Analogues are purpose-built research tools based on naturally occurring biology, engineered to behave differently from the native sequence in specific and defined ways.
What is the difference between selectivity and specificity?
Selectivity refers to a compound’s preference for one receptor subtype over others within the same receptor family. Specificity refers to whether a compound’s effects are attributable to a single defined mechanism or multiple pathways. Neither guarantees the absence of unintended effects. Both describe degrees of preference. For a compound-level illustration of dual receptor selectivity in research, see tirzepatide research overview.
Why does the distinction between in vitro and in vivo matter?
In vitro work establishes whether a compound interacts with a specific target under controlled conditions. In vivo work tests whether that interaction produces measurable effects in a living system. These are different levels of evidence and cannot be treated as equivalent. A finding in cell culture does not predict what happens in an animal model, and a finding in a rodent model does not predict what happens in human biology.
- CONTINUE LEARNING
Explore Related Peptide Topics
Continue building your understanding by exploring related foundational peptide topics.
References & Sources
- Peptide Drug Stability and Half-Life – PubMed Central
- Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion – NCBI
- DPP-4 and Peptide Degradation Mechanisms – PubMed Central
- Peptide Drug Delivery and Bioavailability Challenges – PubMed Central
- Strategies to Improve Peptide Stability and Half-Life – PubMed Central
- Pharmacokinetics and Pharmacodynamic Correlations of Therapeutic Peptides — Clinical Pharmacokinetics (2013)
- Optimizing ADME Properties of Peptide Therapeutics — The AAPS Journal (2015)
- Strategies to Improve Plasma Half-Life of Peptide and Protein Drugs — Amino Acids (2006)
Disclaimer: BioStrata Research provides materials for laboratory research use only. The information in this article is intended strictly for educational and informational purposes within a research context and should not be interpreted as medical advice, treatment guidance, or product claims for human use.